Effects of antipsychotic medications during pregnancy on child development
Developmental effects of antenatal exposure to antipsychotics
This study looks at how taking antipsychotic medications during pregnancy might impact the growth and development of babies, helping moms with severe mental illness understand their treatment options better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11088227 on NIH RePORTER |
What this research studies
This research investigates how antipsychotic medications taken by pregnant women affect the development of their children. It involves observing women with severe mental illness who are treated with antipsychotics compared to those treated with other medications or none at all. The study will track the mothers' psychiatric health and the infants' development through various assessments, including EEG tests and behavioral evaluations. The goal is to provide valuable insights that can help mothers make informed decisions about their treatment during pregnancy.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women with severe mental illness who are considering or currently using antipsychotic medications.
Not a fit: Patients who are not pregnant or those without severe mental illness may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide critical information on the safety and effectiveness of antipsychotic medications during pregnancy, potentially improving maternal and child health outcomes.
How similar studies have performed: While there is ongoing research in this area, the specific effects of antipsychotics during pregnancy on child development remain underexplored, making this study a novel contribution.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Robakis, Thalia K — Icahn School of Medicine at Mount Sinai
- Study coordinator: Robakis, Thalia K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.